OXB to Present at the Leerink Partners Global Healthcare Conference
OXB (LSE: OXB), a leader in cell and gene therapy contract development and manufacturing, is gearing up for an important event in the healthcare sector. The company has announced that Dr. Lucinda Crabtree, its Chief Financial Officer, will engage in a fireside chat at the Leerink Partners Global Healthcare Conference. This event will take place in Miami, where industry leaders gather to discuss the latest trends in healthcare and biotechnology.
Event Details and Online Viewing Options
The fireside chat is scheduled for 2:20 PM EDT / 6:20 PM GMT on March 11. Attendees will gain valuable insights into OXB's innovations and contributions to the field of gene therapy. For those unable to attend in person, the conversation will be broadcasted live via OXB’s Investor Relations website. Following the chat, a replay will also be available, ensuring stakeholders can catch up on the discussion at their convenience.
About OXB and Its Pioneering Role in Cell and Gene Therapy
Having been at the forefront of cell and gene therapy for three decades, OXB is committed to helping its partners develop life-altering therapeutics. The company specializes in viral vector development and manufacturing, key elements in therapeutic efficacy. This expertise includes lentivirus, adeno-associated virus (AAV), and adenovirus production.
Technological Innovations
OXB has showcased unique technologies like the advanced TetraVecta™ system, which is part of their 4th generation lentiviral vector offerings. These cutting-edge solutions enable the production of high-quality vectors essential for innovative treatments. The company’s vast experience positions them as a trusted partner for many of the world’s top pharmaceutical and biotechnology firms.
Commitment to Quality and Regulatory Standards
The cornerstone of OXB's success lies in its robust quality assurance protocols, extensive analytical methodologies, and regulatory expertise. These elements are crucial for the compliance and efficacy of cell and gene therapy products. This commitment is reflected in OXB’s standing as a FTSE4Good constituent, which highlights the company’s dedication to sustainable practices and ethical governance.
Contact Information for Further Inquiries
For media relations or investor inquiries, OXB encourages interested parties to reach out. Sophia Bolhassan, the Head of Investor Relations, is available at +44 (0) 1865 509 737 or via email. Additionally, the company offers support through ICR Healthcare for broader communication channels. Feel free to connect with dedicated representatives for detailed information on the company and its offerings.
Frequently Asked Questions
What is the primary focus of OXB?
OXB specializes in cell and gene therapy, providing contract development and manufacturing services to help clients deliver effective therapies.
When will OXB's presentation occur?
The presentation by Dr. Lucinda Crabtree is scheduled for March 11, with a live webcast available for those wishing to tune in.
Where can I find the live broadcast of the presentation?
The live stream will be accessible on OXB's Investor Relations page under the relevant section for webcasts.
How does OXB ensure high quality in their therapies?
OXB employs stringent quality assurance practices, comprehensive analytical methods, and extensive regulatory knowledge to maintain high standards across its offerings.
What technologies does OXB utilize for vector production?
OXB utilizes several advanced technologies, including the TetraVecta™ system for lentiviral vector production and dual plasmid systems for AAV.
